Progress in the design of selective ATP-competitive kinase inhibitors

Yaoxue Xuebao

Volumn 42, Issue 12, 2007, Pages 1232-1236

  Deng, Xiao qiang ^a,b   Xiang, Ming li ^a,b   Jia, Ruo ^a   Yang, Sheng yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

ATP competitive; Drug design; Protein kinase inhibitor; Specificity

Indexed keywords

ADENOSINE TRIPHOSPHATE; PROTEIN KINASE INHIBITOR;

BINDING COMPETITION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; PROTEIN BINDING; REVIEW; SYNTHESIS;

ADENOSINE TRIPHOSPHATE; BINDING, COMPETITIVE; DRUG DESIGN; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN KINASE INHIBITORS;

EID: 38949092922     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cohen P. Protein kinases - the major drug targets of the twenty-first century? [J]. Nat Rev Drug Disc, 2002,1; 309-315.
2. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure [J]. Science, 2004,303:1800-1805.
3. Gyorgy K, Laszlo O, Daniel E, et al. Signal transduction therapy with rationally designed kinase inhibitors [J]. Curr Signal Transduction Ther, 2006,1:67-95.
4. Li YQ, Feng ZQ, Song HR, et al. Advances in the study of glucokinase and small molecule glucokinase activators [J]. Acta Pharm Sin, 2006,41:390-394.
5. Stadier WM. New targets, therapies, and toxicities: lessons to be learned [J]. J Clin Oncol, 2006,24:4-5.
6. Dumas J. Protein kinase inhibitors: emerging pharmacophores 1997-2000 [J]. Expert Opin Ther Pat, 2001,11: 405-429.
7. Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors [J]. Pharmacol Ther, 1999,82:195-206.
8. Manning G, Whyte DB, Martinez R, et al. The protein. kinase complement of the human genome [J]. Science, 2002,298:1912-1934.
9. Blake RA, Broome MA, Liu XD, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling [J]. Mol Cell Biol, 2000,20:9018-9027.
10. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J]. Nat Med, 1996,2:561-566.
11. Druker, BJ. STI571 (Gleevec) as a paradigm for cancer therapy [J]. Trends Mol Med, 2002,8:S14-S18.
12. Garber K. The second wave in kinase cancer drugs [J]. Nat Biotechnol, 2006,24:127-130.
13. Nolen B, Taylor S, Ghosh G. Regulation of protein kinases: controlling activity through activation segment conformation [J]. Mol Cell, 2004,15:661-675.
14. Hubbard SR. Juxtamembrane autoinhibition in receptor tyrosine kinases [J]. Nat Rev Mol Cell Biol, 2004,5: 464-471.
15. Liao JJ. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors [J]. J Med Chem, 2007,50:409-424.
16. Scapin G. Protein kinase inhibition; different approaches to selective inhibitor design [J]. Curr Drug Targets, 2006,7:1443-1454.
17. Vulpetti A, Bosotti R. Sequence and structural analysis of kinase ATP pocket residues [J]. Il Farmaco, 2004, 59:759-765.
18. Wilson KP, McCaffrey PG, Hsiao K, et al. Structural basis for the specificity of pyridinylimidazole inhibitors of p38 map kinase [J]. Chem Biol, 1997,4:423-431.
19. Lisnock JM, Tebben A, Frantz B, et al. Molecular basis for p38 protein kinase inhibitor specificity [J]. Biochemistry, 1998,37:16573-16581.
20. Natarajan SR, Wisnoski DD, Singh SB, et al. p38MAP kinase inhibitors, part 1: design and development of a new class of potent and highly selective inhibitors based on 3, 4-dihydropyrido [3, 2-d] pyrimidone scaffold [J]. Bioorg Med Chem Lett, 2003,13:273-276.
21. Cohen MS, Zhang C, Shokat KM, et al. Structural bioinformatics-based design of selective, irreversible kinase inhibitors [J]. Science, 2005,308:1318-1321.
22. Bhattacharya SK, Cox ED, Kath JC, et al. Achieving selectivity between highly homologous tyrosine kinases; a novel selective erbB2 inhibitor [J]. Biochem Biophys Res Comm, 2003,307;267-273.
23. Okram B, Nagle A, Adrian FJ, et al. A general strategy for creating "inactive-conformation" Abl inhibitors [J]. Chem Biol, 2006,13:779-786.
24. Gray NS, Wodicka L, Thunnissen AM, et al. Exploiting chemical libraries structure and genomics in the search for kinase inhibitors [J]. Science, 1998,281:533-538.
25. Golebiowski A, Klopfenstein SR, Portlock DE. Lead compounds discovered from libraries; Part 2 [J]. Curr Opin Chem Biol, 2003,7:308-325.
26. Honma T, Hayashi K, Aoyama T, et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design [J]. J Med Chem, 2001,44:4615-4627.
27. Blum G, Gazit A, Levitzki A. Substrate competitive inhibitors of IGF-I receptor kinase [J]. Biochemistry, 2000,39:15705-15712.
28. Gumireddy K, Reddy MV, Cosenza SC, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent [J]. Cancer Cell, 2005,7:275-286.
29. Adria'n JF, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-Abl-dependent cell proliferation [J]. Nat Chem Biol, 2006,2:95-102.
30. Parang K, Cole PA. Designing bisubstrate analog inhibitors for protein kinases [J]. Pharmacol Ther, 2002,93:145-157.